{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-117669","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.176140+00:00","generated_at":"2026-06-08T03:48:39.380235+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioXcel posts Q3 net loss $50.5M, aligns with FDA on Phase 3 for agitation in Alzheimer's dementia","bullets":["Q3 net loss $50.5M vs $41.8M YoY; IGALMI net revenue ~$341k; cash $90M, funds through mid-2024.","FDA alignment for Phase 3 trial of BXCL501 (60 mcg) for Alzheimer's agitation in at-home setting; ~100 patients, 4 weeks.","SERENITY III program plans Phase 3 trial with 120 mcg dose (approved IGALMI dose) for at-home agitation in bipolar/schizophrenia.","Binding term sheet with Oaktree and QIA to amend financing; potential access to more capital, adjusted revenue covenants.","OnkosXcel reports positive Phase 2 overall survival for BXCL701 in prostate cancer; evaluating strategic options."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-117669","json":"https://secwatch.observer/filing/0001104659-23-117669.json","markdown":"https://secwatch.observer/filing/0001104659-23-117669.md","text":"https://secwatch.observer/filing/0001104659-23-117669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923117669/0001104659-23-117669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923117669/tm2330471d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:48:39.380235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb2883081d95871e47c4eec90e937f779a086af4","claim":"BioXcel Therapeutics, Inc. reported third quarter ended Sept. 30, 2023 results: revenue approximately $341,000, net income $50.5 million.","evidence_excerpt":"OnkosXcel Therapeutics, including potential financing, strategic partnership, or M&A. 2 Third Quarter 2023 Financial Results Net Revenue: Net revenue of IGALMI was approximately $341,000 for the quarter. Research and Development (R&D) Expenses: R&D expenses were $19.6 million for the third quarter of 2023, compared to $22.1 million for the same period in 2022. The","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923117669/0001104659-23-117669-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended Sept. 30, 2023"},{"label":"Revenue","value":"approximately $341,000"},{"label":"Net income","value":"$50.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}